Melbourne, Australia;
7 April 2021 – Key Chinese Patent Covering OBM-1701 Allowed
Melbourne, Australia; 8 January 2021 – Key Chinese Patent covering OBM-17xx Granted
January 8, 2021Melbourne, Australia; 2 June 2021 – Key EU Patent covering OBM-1701 Granted
June 2, 2021Oculus Biomed Limited (“OBM”) is pleased to announce the application of the Chinese Patent which covers its OBM-1701 has been allowed. The term of the Chinese patent extends its patent protection to April 2036 and covers OBM-1701 and its analogues and their use in disorders associated with diverging angiogenesis, including eye-related diseases such as wet age-related macular degeneration (wet AMD or wAMD) and diabetic macular edema (DME). Corresponding patent applications have already been granted in 7 other countries, including USA, Canada, Japan, South Korea, Australia, etc and are pending in other countries territories, including EU etc.
